{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:05:32Z","timestamp":1761609932181},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.autrev.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T09:14:33Z","timestamp":1528276473000},"page":"791-795","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus"],"prefix":"10.1016","volume":"17","author":[{"given":"Sara","family":"Tenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fabbroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filomena","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.02.010_bb0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11310780-000000000-00000","article-title":"Cutaneous lupus erythematosus: issues in diagnosis and treatment","volume":"10","author":"Walling","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","article-title":"Cutaneous lupus erythematosus: diagnosis and treatment","volume":"27","author":"Okon","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jaut.2014.01.021","article-title":"The classification and diagnosis of cutaneous lupus erythematosus","volume":"48-49","author":"Kuhn","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2018.02.010_bb0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jaad.2017.02.030","article-title":"Development of classification criteria for discoid lupus erythematosus: results of a Delphi exercise","volume":"77","author":"Elman","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0025","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.autrev.2017.05.009","article-title":"Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema","volume":"16","author":"Zhang","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.02.010_bb0030","article-title":"Drugs for discoid lupus erythematosus","volume":"5","author":"Jessop","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2018.02.010_bb0035","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.autrev.2012.10.005","article-title":"Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus","volume":"12","author":"Sigges","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.02.010_bb0040","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/dth.12358","article-title":"Review of treatment for discoid lupus erythematosus","volume":"29","author":"Garza-Mayers","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2018.02.010_bb0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12016-009-8155-9","article-title":"Evidence for the use of intravenous immunoglobulins\u2013a review of the literature","volume":"38","author":"Kivity","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0050","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2015.11.009","article-title":"Intravenous immunoglobulins and antiphospholipid syndrome: how, when and why? A review of the literature","volume":"15","author":"Tenti","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2018.02.010_bb0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.autrev.2015.03.005","article-title":"Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature","volume":"14","author":"Guidelli","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2018.02.010_bb0060","first-page":"S304","article-title":"High-dose immunoglobulins in the treatment of refractory cutaneous lupus erythematosus: open trial in 5 patients","volume":"38","author":"Piette","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.02.010_bb0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/096120339700600414","article-title":"Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus","volume":"6","author":"De Pit\u00e0","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.02.010_bb0070","first-page":"255","article-title":"Intravenous immunoglobulin therapy in dermatology: overview and center experience","volume":"73","author":"Wollina","year":"1998","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0075","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archderm.135.9.1124","article-title":"High-dose intravenous immunoglobulin in cutaneous lupus erythematosus","volume":"135","author":"G\u00e9n\u00e9reau","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0080","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin\u2013clinical and serologic response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2018.02.010_bb0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09546630310018789","article-title":"Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE)","volume":"15","author":"Goodfield","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2018.02.010_bb0090","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/00015550510037071","article-title":"Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus","volume":"85","author":"Kreuter","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0095","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10067-006-0222-5","article-title":"Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative","volume":"26","author":"Lampropoulos","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0100","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.4081\/dr.2015.5804","article-title":"Efficacy of intravenous immunoglobulin monotherapy in patients with cutaneous lupus erythematosus: results of proof-of-concept study","volume":"7","author":"Ky","year":"2015","journal-title":"Dermatol Rep"},{"key":"10.1016\/j.autrev.2018.02.010_bb0105","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2018.02.010_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.oooo.2017.08.012","article-title":"Multiple primary squamous cell carcinomas of the lower lip and tongue arising in discoid lupus erythematosus: a case report","volume":"125","author":"Arvanitidou","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0115","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.02.010_bb0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/HAB-160293","article-title":"The effect of Intravenous Immunoglobulin (IVIG) on \\textit{ex vivo} activation of human leukocytes","volume":"24","author":"Basyreva","year":"2016","journal-title":"Hum Antibodies"},{"key":"10.1016\/j.autrev.2018.02.010_bb0125","first-page":"55","article-title":"Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases","volume":"10","author":"Sherer","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2018.02.010_bb0130","first-page":"877","article-title":"Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy","volume":"31","author":"Tenti","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2018.02.010_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/08916930500059633","article-title":"IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients","volume":"38","author":"Shoenfeld","year":"2005","journal-title":"Autoimmunity"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218301320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T00:59:49Z","timestamp":1693702789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218301320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1568997218301320"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.02.010","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}